JAQUE

This brand name is authorized in Brazil

Active ingredients

The drug JAQUE contains a combination of these active pharmaceutical ingredients (APIs):

1 Cyproterone
UNII 4KM2BN5JHF - CYPROTERONE ACETATE

Cyproterone acetate acts as an antiandrogen by blocking androgen receptors. It also has progestogenic activity, which exerts a negative feedback effect on hypothalamic receptors, so leading to a reduction in gonadotrophin release, and hence to diminished production of testicular androgens. Sexual drive and potency are reduced and gonadal function is inhibited.

Read about Cyproterone
2 17 alpha-Ethinylestradiol
UNII 423D2T571U - ETHINYL ESTRADIOL

Ethinylestradiol is chemically and biologically identical to endogenous human oestradiol. It substitutes for the loss of estrogen production in menopausal women, and alleviates menopausal symptoms. Estrogens prevent bone loss following menopause or ovariectomy.

Read about 17 alpha-Ethinylestradiol

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
G03HB01 Cyproterone and estrogen G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03H Antiandrogens → G03HB Antiandrogens and estrogens
Discover more medicines within G03HB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: BR Cรขmara de Regulaรงรฃo do Mercado de Medicamentos Identifier(s): 541818070086104

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.